2014
Combined hormonal contraception and risk of venous thromboembolism within the first year following pregnancy
Petersen J, Bergholt T, Nielsen A, Paidas M, Løkkegaard E. Combined hormonal contraception and risk of venous thromboembolism within the first year following pregnancy. Thrombosis And Haemostasis 2014, 112: 73-78. PMID: 24499991, DOI: 10.1160/th13-09-0797.Peer-Reviewed Original ResearchConceptsVenous thromboembolismHormonal contraceptivesIncidence ratiosFirst-time venous thromboembolismCrude incidence ratioCombined oral contraceptivesNationwide retrospective cohortConfirmed pregnanciesOral contraceptivesRetrospective cohortHormonal contraceptionPuerperal periodAbsolute riskWeeks postpartumDanish womenMAIN OUTCOMEThromboembolismPregnancyContraceptivesOne-yearUnique registryFirst yearRiskBirthRegistry
2002
The use of coagulation activation markers (soluble fibrin polymer, TpPTM, prothrombin fragment 1.2, thrombin–antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders
Arkel Y, Paidas M, Ku D. The use of coagulation activation markers (soluble fibrin polymer, TpPTM, prothrombin fragment 1.2, thrombin–antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. Blood Coagulation & Fibrinolysis 2002, 13: 199-205. PMID: 11943933, DOI: 10.1097/00001721-200204000-00005.Peer-Reviewed Original ResearchMeSH KeywordsActivated Protein C ResistanceAdolescentAdultAgedAged, 80 and overAntiphospholipid SyndromeAntithrombin IIIAntithrombin III DeficiencyAutoimmune DiseasesBiomarkersEnzyme-Linked Immunosorbent AssayFactor VFemaleFibrinFibrin Fibrinogen Degradation ProductsHumansHyperhomocysteinemiaMaleMiddle AgedPeptide FragmentsPeptide HydrolasesProtein C DeficiencyProtein S DeficiencyProthrombinRiskSolubilityThrombophiliaConceptsCoagulation activation markersActivation markersAssessment of hypercoagulabilityPercentage of patientsProthrombotic disordersVascular eventsConsecutive patientsThrombophilic abnormalitiesThrombotic riskPatientsSoluble fibrin polymersTPP levelsMean levelsMarkersAbnormalitiesFibrin polymersHypercoagulability